Flovent®
Fluticasone propionate is an ICS for maintenance treatment of asthma. Available as inhaler and nasal spray for different indications.
| Dosage Form | Inhaler (MDI / DPI) |
| Strength | 44, 110, 220 mcg per actuation (MDI); 50, 100, 250 mcg (DPI) |
| Storage | Store at 20–25°C. |
| Category | Respiratory |
| Availability | Available for Transfer |
Maintenance treatment of asthma (prophylactic therapy in patients ≥4 years).
Potent glucocorticoid that activates glucocorticoid receptors to suppress inflammatory gene expression. Has high topical anti-inflammatory potency with low systemic bioavailability.
Each Burrard Pharmaceuticals technology transfer package for Fluticasone includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.